Christine Ring
General Counsel at Nurix Therapeutics, Inc. (NRIX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Oct 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 5,7869,110 held (−39%) | $23.19 | $134K | -3.6% |
| Sep 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 5,3879,510 held (−36%) | $25.69 | $138K | -13.0% |
| Sep 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 4009,110 held (−4%) | $26.64 | $11K | -16.1% |
| Aug 3SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 16,5899,110 held (−65%) | $23.05 | $382K | -3.0% |
| Jul 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 3,84719,912 held (−16%) | $23.38 | $90K | -4.4% |
| Jul 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 11,00813,579 held (−45%) | $23.56 | $259K | -5.1% |
| Jun 25SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 28,93513,579 held (−68%) | $20.06 | $580K | +11.4% |
| Jun 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 8,14813,579 held (−38%) | $16.60 | $135K | +34.6% |
| May 4SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 8,14818,305 held (−31%) | $16.96 | $138K | +31.8% |
| May 1SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 5,39426,453 held (−17%) | $16.76 | $90K | +33.4% |
| Apr 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 3,21431,847 held (−9%) | $16.65 | $54K | +34.2% |
| Apr 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 8,14826,453 held (−24%) | $15.24 | $124K | +46.7% |
| Mar 2SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 8,14834,601 held (−19%) | $15.44 | $126K | +44.8% |
| Feb 9SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 14,26142,749 held (−25%) | $16.66 | $238K | +34.2% |
| Jan 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 4,33357,098 held (−7%) | $16.58 | $72K | +34.8% |
| Jan 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 8857,010 held (−0%) | $17.37 | $2K | +28.7% |
| Jan 20SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 3,76050,897 held (−7%) | $18.42 | $69K | +21.3% |
| Dec 18SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 3,56051,097 held (−7%) | $17.87 | $64K | +25.1% |
| Dec 18SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 20050,897 held (−0%) | $18.56 | $4K | +20.4% |
| Nov 24SEC | NRIXNurix Therapeutics, Inc. | Sell Plan | 37,60050,897 held (−42%) | $17.07 | $642K | +30.9% |
| Oct 30SEC | NRIXNurix Therapeutics, Inc. | Sell | 3,64450,897 held (−7%) | $12.80 | $47K | +74.6% |
- Sell
General Counsel Christine Ring sold $134K of NRIX at $23.19 — cuts the stake by 39%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Christine Ring sold $138K of NRIX at $25.69 — cuts the stake by 36%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Christine Ring sold $11K of NRIX at $26.64 — pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Christine Ring sold $382K of NRIX at $23.05 — cuts the stake by 65%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Christine Ring sold $259K of NRIX at $23.56 — cuts the stake by 45%; pre-scheduled 10b5-1 plan sale.
- Sell
General Counsel Christine Ring sold $580K of NRIX at $20.06 — cuts the stake by 68%; pre-scheduled 10b5-1 plan sale.